Index RUT
P/E -
EPS (ttm) -2.92
Insider Own 3.71%
Shs Outstand 64.41M
Perf Week 5.58%
Market Cap 1.41B
Forward P/E -
EPS next Y -2.87
Insider Trans -2.15%
Shs Float 62.02M
Perf Month 7.23%
Income -165.00M
PEG -
EPS next Q -0.66
Inst Own 74.78%
Short Float 14.25%
Perf Quarter 77.51%
Sales 62.30M
P/S 22.68
EPS this Y -4.56%
Inst Trans -4.24%
Short Ratio 8.44
Perf Half Y 170.86%
Book/sh 5.76
P/B 3.81
EPS next Y -3.55%
ROA -38.30%
Short Interest 8.84M
Perf Year 133.16%
Cash/sh 6.88
P/C 3.19
EPS next 5Y -
ROE -52.33%
52W Range 4.22 - 24.38
Perf YTD 112.60%
Dividend Est. -
P/FCF -
EPS past 5Y -59.00%
ROI -42.14%
52W High -10.00%
Beta 2.22
Dividend TTM -
Quick Ratio 5.57
Sales past 5Y 27.29%
Gross Margin 75.73%
52W Low 419.91%
ATR (14) 1.49
Dividend Ex-Date -
Current Ratio 5.57
EPS Y/Y TTM 1.63%
Oper. Margin -287.47%
RSI (14) 56.80
Volatility 7.27% 7.17%
Employees 284
Debt/Eq 0.08
Sales Y/Y TTM 2.25%
Profit Margin -264.84%
Recom 1.33
Target Price 28.42
Option/Short Yes / Yes
LT Debt/Eq 0.06
EPS Q/Q -59.61%
Payout -
Rel Volume 0.56
Prev Close 21.04
Sales Surprise -45.30%
EPS Surprise -11.85%
Sales Q/Q -60.58%
Earnings Jul 11 AMC
Avg Volume 1.05M
Price 21.94
SMA20 3.55%
SMA50 18.44%
SMA200 81.59%
Trades
Volume 590,599
Change 4.28%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-26-23 Resumed
Oppenheimer
Outperform
$25
Mar-09-23 Initiated
Barclays
Overweight
$20
Feb-28-23 Initiated
Oppenheimer
Outperform
$25
Oct-11-22 Initiated
Morgan Stanley
Equal-Weight
$11
May-31-22 Upgrade
Wells Fargo
Equal Weight → Overweight
$25
Feb-10-22 Initiated
Wells Fargo
Equal Weight
$28
Dec-29-21 Initiated
H.C. Wainwright
Buy
$62
Oct-14-21 Initiated
SVB Leerink
Outperform
$50
Jun-04-21 Resumed
Robert W. Baird
Outperform
$45 → $46
Apr-30-21 Resumed
Piper Sandler
Overweight
$60
Apr-30-21 Initiated
RBC Capital Mkts
Outperform
$42
Apr-14-21 Initiated
Berenberg
Buy
Nov-19-20 Initiated
Robert W. Baird
Outperform
$40
Aug-18-20 Initiated
Stifel
Buy
$34
Aug-18-20 Initiated
Piper Sandler
Overweight
$40
Aug-18-20 Initiated
Needham
Buy
$35
Aug-18-20 Initiated
JP Morgan
Overweight
$35
Show Previous Ratings
Jul-25-24 09:55AM
Jul-16-24 12:00PM
Jul-11-24 05:10PM
04:00PM
Jul-08-24 07:00AM
07:02PM
Loading…
Jun-20-24 07:02PM
05:26PM
Jun-19-24 05:05AM
Jun-17-24 04:06PM
(Investor's Business Daily)
+20.60%
08:45AM
(Investor's Business Daily)
07:40AM
Jun-16-24 05:30AM
Jun-10-24 07:00AM
May-29-24 07:00AM
May-28-24 07:00AM
04:41PM
Loading…
May-20-24 04:41PM
04:00PM
10:21AM
May-14-24 10:00AM
07:39AM
May-07-24 07:00AM
Apr-16-24 06:21PM
Apr-11-24 11:38PM
04:00PM
Apr-10-24 11:53AM
09:29AM
08:31AM
08:10AM
07:00AM
Apr-09-24 01:15PM
07:00AM
Loading…
07:00AM
Apr-03-24 07:00AM
Apr-02-24 07:00AM
Mar-25-24 07:00AM
Mar-20-24 09:40AM
Mar-11-24 07:00AM
Mar-06-24 04:00PM
(GlobeNewswire) +17.39%
-7.41%
Mar-05-24 04:30PM
Feb-23-24 06:20AM
Feb-16-24 07:04PM
Feb-15-24 05:10PM
04:00PM
Feb-01-24 04:01PM
10:01AM
Jan-16-24 04:01PM
Jan-08-24 07:00AM
Jan-02-24 04:01PM
Dec-21-23 05:01PM
Dec-13-23 04:32PM
Dec-11-23 12:00PM
Dec-04-23 04:01PM
Nov-07-23 04:01PM
Nov-02-23 09:00AM
Nov-01-23 04:01PM
Oct-18-23 09:35AM
Oct-14-23 06:01AM
Oct-12-23 05:15PM
04:01PM
Oct-11-23 07:09AM
Oct-05-23 09:35AM
Oct-04-23 09:35AM
Sep-28-23 10:00AM
Sep-20-23 09:30AM
Sep-15-23 12:00PM
09:55AM
Sep-11-23 12:10PM
Sep-08-23 05:32AM
Sep-07-23 07:00AM
Aug-31-23 10:12PM
04:01PM
Aug-02-23 05:01AM
Jul-24-23 09:55AM
Jul-15-23 08:12AM
Jul-13-23 05:15PM
04:01PM
Jul-11-23 10:00AM
Jun-29-23 10:00AM
Jun-14-23 07:00AM
May-25-23 06:28AM
May-24-23 09:55AM
May-09-23 04:01PM
(GlobeNewswire) +5.21%
+5.46%
May-04-23 09:55AM
Apr-19-23 06:05AM
Apr-18-23 09:55AM
Apr-17-23 02:30PM
Apr-13-23 05:15PM
04:01PM
Apr-11-23 04:01PM
Mar-30-23 10:00AM
Mar-21-23 10:05AM
03:49AM
Mar-20-23 12:17PM
09:00AM
08:30AM
Mar-17-23 09:22AM
Mar-14-23 04:45PM
Mar-06-23 04:01PM
Feb-27-23 11:57AM
Feb-09-23 05:35PM
04:15PM
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rape, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Ring Christine Chief Legal Officer Jul 01 '24 Option Exercise 1.86 5,760 10,714 25,598 Jul 01 06:35 PM Ring Christine Chief Legal Officer Jul 01 '24 Sale 20.81 5,760 119,837 19,838 Jul 01 06:35 PM van Houte Hans Chief Financial Officer Jun 20 '24 Sale 20.01 20,000 400,216 48,333 Jun 20 04:58 PM Ring Christine Chief Legal Officer Jun 13 '24 Option Exercise 1.86 1,864 3,467 21,702 Jun 13 06:39 PM Ring Christine Chief Legal Officer Jun 13 '24 Sale 17.02 1,864 31,721 19,838 Jun 13 06:39 PM Ring Christine Chief Legal Officer Jun 12 '24 Option Exercise 1.86 1,900 3,534 21,738 Jun 12 07:30 PM Ring Christine Chief Legal Officer Jun 12 '24 Sale 17.01 1,900 32,319 19,838 Jun 12 07:30 PM Ring Christine Chief Legal Officer Jun 05 '24 Option Exercise 1.86 400 744 20,238 Jun 05 06:01 PM Ring Christine Chief Legal Officer Jun 05 '24 Sale 17.00 400 6,801 19,838 Jun 05 06:01 PM Ring Christine Chief Legal Officer Jun 03 '24 Option Exercise 1.86 1,596 2,969 21,434 Jun 03 06:36 PM Ring Christine Chief Legal Officer Jun 03 '24 Sale 17.01 1,596 27,153 19,838 Jun 03 06:36 PM van Houte Hans Chief Financial Officer May 02 '24 Sale 12.83 3,499 44,878 68,333 May 02 06:01 PM Hansen Gwenn Chief Scientific Officer Apr 30 '24 Option Exercise 0.00 5,206 0 41,608 Apr 30 06:33 PM van Houte Hans Chief Financial Officer Apr 30 '24 Option Exercise 0.00 4,886 0 73,219 Apr 30 06:33 PM Ring Christine Chief Legal Officer Apr 30 '24 Option Exercise 0.00 3,924 0 21,351 Apr 30 06:33 PM Hansen Gwenn Chief Scientific Officer Apr 30 '24 Sale 12.04 2,007 24,169 39,601 Apr 30 06:33 PM Ring Christine Chief Legal Officer Apr 30 '24 Sale 12.04 1,513 18,220 19,838 Apr 30 06:33 PM van Houte Hans Chief Financial Officer Apr 30 '24 Sale 12.04 1,387 16,703 71,832 Apr 30 06:33 PM van Houte Hans Chief Financial Officer Feb 16 '24 Sale 10.02 6,812 68,223 68,333 Feb 16 07:20 PM van Houte Hans Chief Financial Officer Jan 30 '24 Option Exercise 0.00 4,886 0 76,816 Jan 30 06:53 PM Hansen Gwenn Chief Scientific Officer Jan 30 '24 Option Exercise 0.00 5,207 0 38,736 Jan 30 06:52 PM Ring Christine Chief Legal Officer Jan 30 '24 Option Exercise 0.00 3,924 0 19,187 Jan 30 06:52 PM Hansen Gwenn Chief Scientific Officer Jan 30 '24 Sale 7.99 2,334 18,649 36,402 Jan 30 06:52 PM Ring Christine Chief Legal Officer Jan 30 '24 Sale 7.99 1,760 14,063 17,427 Jan 30 06:52 PM van Houte Hans Chief Financial Officer Jan 30 '24 Sale 7.99 1,671 13,352 75,145 Jan 30 06:53 PM van Houte Hans Chief Financial Officer Dec 20 '23 Sale 10.00 3,541 35,421 71,930 Dec 21 05:19 PM van Houte Hans Chief Financial Officer Dec 19 '23 Sale 10.00 10,906 109,093 75,471 Dec 20 04:55 PM Hansen Gwenn Chief Scientific Officer Oct 31 '23 Sale 5.20 1,633 8,487 33,529 Nov 01 04:40 PM Ring Christine Chief Legal Officer Oct 31 '23 Sale 5.20 1,232 6,403 15,263 Nov 01 04:40 PM van Houte Hans Chief Financial Officer Oct 31 '23 Sale 5.20 1,080 5,613 86,377 Nov 01 04:41 PM van Houte Hans Chief Financial Officer Oct 30 '23 Option Exercise 0.00 4,886 0 87,457 Nov 01 04:41 PM Hansen Gwenn Chief Scientific Officer Oct 30 '23 Option Exercise 0.00 5,207 0 35,162 Nov 01 04:40 PM Ring Christine Chief Legal Officer Oct 30 '23 Option Exercise 0.00 3,924 0 16,495 Nov 01 04:40 PM Hansen Gwenn Chief Scientific Officer Jul 31 '23 Sale 9.65 1,884 18,189 29,955 Aug 01 04:26 PM Ring Christine General Counsel Jul 31 '23 Sale 9.65 1,420 13,710 12,544 Aug 01 04:27 PM van Houte Hans Chief Financial Officer Jul 31 '23 Sale 9.65 1,245 12,020 82,571 Aug 01 04:28 PM van Houte Hans Chief Financial Officer Jul 30 '23 Option Exercise 0.00 4,886 0 83,816 Aug 01 04:28 PM Ring Christine General Counsel Jul 30 '23 Option Exercise 0.00 3,924 0 13,964 Aug 01 04:27 PM Hansen Gwenn Chief Scientific Officer Jul 30 '23 Option Exercise 0.00 5,207 0 31,839 Aug 01 04:26 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite